Patients warned not to turn to fake weight loss jabs after UK Mounjaro price hike

Medical experts warned the British not to Turn in false weight kicks After the fears the Mounjaro Price Randonnée could make him unaffordable for people “who already find it difficult to pay”.

The cost of the drug, nicknamed the “King Kong” weight loss Medicine is set to Triple in the United Kingdom After WE-The companies have equalized market costs around the world.

The one -month offer of the highest doses of JAB will drop from £ 122 to £ 330, an increase of 170%.

Although this will not affect patients prescribed JAB on the NHS, this will affect thousands of people who are currently buying the medication in private.

Professor Claire Anderson, president of the Royal Pharmacist Society (RPS), said that the price increase was likely to make the blows out of reach for people who already had trouble affording them.

“It is reassuring that NHS patients with obesity and type 2 diabetes will continue to access Mounjaro,” she told The Independent.

“However, the increase in private prescription costs can make Mounjaro unaffordable for people in disadvantaged areas that already have trouble paying for this.”

She said that the RPS urges anyone planning to get Mounjaro to do so only from a British pharmacy recorded with the General Pharmaceutical Council and with a valid prescription.

She warned that counterfeits could be harmful or non -effective and have said: “counterfeit drugs from unregulated sources have serious health risks – they may contain incorrect doses, harmful substances or no active ingredient.”

She added that if patients online, check the site displays the official GPHC logo binding the GPHC register.

Professor Kamila Hawthorne, president of the Royal College of GPS, also urged patients to use only renowned outlets and to speak with their private supplier if they are concerned about the potential price increases.

She said: “If they access medication through questionable online sources, or without a prescription, this may be a real threat to the safety of a patient. In some cases, people may not buy what they think is, which is really dangerous.”

False jabs for sale in the United Kingdom are already a huge concern, with thousands of fraudulent online pharmacies The sale of these products having been discovered.

False versions of Ozempicanother Popular Jab weight loss brandWere found sold for as little as £ 13.70 per dose, as well as counterfeit versions of other brands, including Rybelsus and Metformin pills, offered from 24P.

Avast researchers, a brand of cybersecurity from the company Gen, which conducted the investigation, warned of The “dangerous” threat The global scam involving more than 5,000 false pharmacy sites this year, which they say, are led by criminal networks.

False blows can be dangerous because they are not regulated, which means that there is no way to know what is and how they are produced.

According to Lloyds Pharmacy, false jabs could contain incorrect doses, bad medication or no medication. There is also a risk that they could contain bacteria or impurities.

The Regulatory Agency for Medicines and Health Products (MHRA) also said that they have received reports from hospitalized people after using potentially false medicines.

He said: “The serious side effects reported from those hospitalized, including hypoglycemic shock and coma, indicate that pens can contain insulin rather than semaglutide.”

It arrives in the middle of the rapid rise in weight loss drugs in the United Kingdom – with around 1.5 million people, 4% of households, currently using them.

These weight loss injections, also called GLP-1 receptor agonists, work by imitating the natural hormone that regulates blood sugar, appetite and digestion.

In June, the NHS Mounjaro offered to obese patients with a BMI of more than 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes.

Over the next three years, around 240,000 patients should be eligible for treatment.

The owner of Mounjaro, Eli Lily, said that he would not increase the price paid by the NHS, and that he was working with private health care providers to maintain access to the JAB.

This decision reflects how the pharmaceutical industry sails in policy changes in the United States, by far its most lucrative market.

This comes after the administration of Donald Trump complained of “foreign freeladers” that count on the United States to pay more for medicine.